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Current oral cholera vaccines induce lower protective efficacy and shorter duration of protection against cholera thanwild-type infec-
tion provides, and this difference ismost pronounced in young children.Despite this, there are limited data comparing immune re-
sponses in children followingwild-type disease versus vaccination, especiallywith regard tomemory responses associatedwith long-
term immunity.Here, we report a comparison of immune responses in young children (2 to 5 years of age;n 20) and older children
(6 to 17 years of age;n 20) given twodoses of an oral killed cholera vaccine containing recombinant cholera toxinB subunit (CtxB)
14 days apart and compare these responses to those induced in similarly aged children recovering from infectionwithVibrio cholerae
O1Ogawa inBangladesh.We found that the two vaccine groups had comparable vibriocidal and lipopolysaccharide (LPS)-specific
plasma antibody responses. Vaccinees developed lower levels of IgGmemoryB cell (MBC) responses against CtxBbut no significant
MBC responses against LPS. In contrast, children recovering fromnatural cholera infection developed prominent LPS IgG and IgA
MBC responses, aswell as CtxB IgGMBC responses. PlasmaLPS IgG, IgA, and IgM responses, aswell as vibriocidal responses, were
also significantly higher in children following disease than after vaccination.Our findings suggest that acute andmemory immune
responses following oral cholera vaccination in children are significantly lower than those observed followingwild-type disease, espe-
cially responses targeting LPS. These findingsmay explain, in part, the lower efficacy of oral cholera vaccination in children.
Cholera is a dehydrating illness caused by infection with the O1orO139 serogroup ofVibrio cholerae. It is a disease of poverty,
made worse in urban areas of endemicity by the overcrowding of
informal housing settlements or slums in high-risk populations
(27). Each year around the world, 2 to 3 million people are in-
fected, and up to 130,000 die from cholera (41, 43). Although
cholera is seen in all age groups, in areas of endemicity, children
under 5 years of age have a large burden of disease (10).
The World Health Organization has recently updated its posi-
tion statement on the use of cholera vaccines (42), and cholera
vaccination is now recommended for inclusion in integrated chol-
era control programs. Two whole-cell oral killed cholera vaccines
(OCVs) are currently internationally available: Dukoral (WC-
rBS; Crucell, Sweden), a mono-serogroup killed V. cholerae O1
supplemented with 1 mg/dose of recombinant cholera toxin B
subunit (CtxB), and Shanchol (bivWC; Sanofi Aventis/Shantha
Biotechnics, India), a bivalent serogroup killed V. cholerae O1/
O139 vaccine not supplemented with additional CtxB (35). WC-
rBS is licensed in over 60 countries while bivWC is licensed in
India and was recently prequalified by the WHO. A Cochrane
review of killed whole-cell OCV studies estimates that vaccine
efficacy in the second year after vaccination was 66% for all ages
but only 38% for children of 5 years of age (36). A recent field
study of bivWC in Kolkata, India, demonstrated 66% protective
efficacy over 3 years of follow-up; however, the youngest children
(5 years of age) had only 43% protective efficacy, with no signif-
icant protection in the third year of follow-up (37). The mecha-
nism behind these differences in vaccine efficacy between age
groups remains to be elucidated and better understood.
Vibriocidal, lipopolysaccharide (LPS) IgA-specific, and CtxB
IgA-specific responses have been correlated with protection from
V. cholerae O1 infection in an observational study of household
contacts of cholera patients in Bangladesh (14); however, such
serological responses wane rapidly in the months after infection
and vaccination (32) and are unlikely to be determinants of long-
term protection. It is hypothesized that memory B cells (MBCs)
are the mediators of a rapid anamnestic immune response on
reexposure and that they are associated with duration of protec-
tion following infection and vaccination (17).We have previously
demonstrated that in adults hospitalized with V. cholerae infec-
tion, MBC responses to V. cholerae antigens persist up to 1 year,
the last period evaluated, longer than that of any other known
markers of cholera immunity (13). In individuals with wild-type
V. cholerae infection, we have recently shown that levels of V.
cholerae antigen-specific memory B cells are comparable between
younger children and older children and adults (22), suggesting
that an optimal vaccination strategy could theoretically induce
protective immunity in both younger and older children. Despite
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a number of studies evaluating serological parameters of OCV
immunogenicity in children (5, 12, 39) and one of MBC re-
sponses to OCV in adults (2), there are currently no data on
memory B cell responses in children receiving oral cholera vac-
cination. Therefore, the aims of this study were to evaluate
acute-phase immune responses in pediatric recipients of an
OCV, including characterizingmemory B cell responses, and to
compare these responses with those seen in children with chol-
era in Bangladesh.
MATERIALS AND METHODS
Study design and subject enrollment. Following a process of informed
consent of parents/guardians, we enrolled 20 healthy young children
(aged 2 to 5 years) and 20 healthy older children (aged 6 to 17 years) from
an urban informal settlement area of Dhaka, Bangladesh. Study partici-
pants were administered two doses of the licensed OCV Dukoral (WC-
rBS; Crucell, Sweden) 14 days apart. Children were excluded if they had a
Z score of less than2 (for those of5 years of age), a history of gastro-
intestinal disorder, any history of parasitic infection, suffered from any
diarrheal disease in the past 2 weeks, or had any febrile illness or antibiotic
usage in the past week. Prior to vaccination, subjects were screened for
evidence of recent enteric infections. Stool specimens were collected and
screened for the presence of V. cholerae O1, enterotoxigenic Escherichia
coli (ETEC), Salmonella spp., and Shigella spp. using standard microbio-
logical techniques (6). If stool and symptom screenings were negative,
participants were administered the vaccine. We obtained blood samples
before vaccination (day 0), at 3 days after the first dose of vaccine, and at
7 and 30 days after the second dose of vaccine (Fig. 1). At each time point,
we assayed vibriocidal antibodies and responses against V. cholerae O1
antigens in plasma. We also assessed antigen-specific IgG and IgA mem-
ory B cells before vaccination and 30 days after the second dose of vacci-
nation, as described below.
We compared immune responses of the vaccinees to those of children,
matched by age group, hospitalized with severe acute watery diarrhea and
stool culture positive forV. choleraeO1Ogawa (22). All study participants
were of the same socio-economic status. We assessed immune responses
in patients on days 2, 7, and 30 following presentation.
These studies were approved by the Research Review Committee
and Ethical Review Committee of the International Centre for Diar-
rheal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh,
and the Institutional Review Board of the Massachusetts General Hos-
pital, Boston, MA.
Isolation of PBMCs. From diluted heparinized blood, we separated
peripheral blood mononuclear cells (PBMCs) and plasma by density gra-
dient centrifugation on Ficoll-Isopaque (Pharmacia, Piscataway, NJ). We
stored plasma at 70°C for immunological analyses. We washed and
suspended the isolated PBMCs at a concentration of 107 cells/ml in RPMI
complete medium (Gibco, Carlsbad, CA) containing 10% heat-inacti-
vated fetal bovine serum (FBS; HyClone, Logan, UT) and assessed mem-
ory B cell responses in a culture-based assay as described below.
Vibriocidal antibody assay. For both vaccinees and patients, wemea-
sured vibriocidal antibody titers in plasma using guinea pig complement
andV. choleraeO1Ogawa (X-25049) as the target organism, as previously
described (31). We defined the vibriocidal titer as the reciprocal of the
highest dilution resulting in50% reduction of the optical density com-
pared to that of control wells without plasma. We considered individuals
showing a4-fold increase in vibriocidal titer compared to their baseline
to be responders.
Detection of cholera antigen-specific antibody levels in plasma.We
measured plasma CtxB- and LPS-specific IgA, IgG, and IgM antibody
responses using a standardized enzyme-linked immunosorbent assay
(ELISA) technique as previously described (31). In brief, we coated 96-
well polystyrene plates (Nunc F) with either V. cholerae O1 Ogawa LPS
(2.5 g/ml) or 0.3 nM ganglioside GM1 overnight, followed by recombi-
nant CtxB (rCtxB) subunit (0.5 g/ml; gifts from A. M. Svennerholm,
University of Gothenburg, Sweden). We added 100 l of plasma (diluted
1:25 for LPS and 1:100 for CtxB in 0.1% bovine serum albumin in phos-
phate-buffered saline–Tween) per well and used horseradish peroxidase-
conjugated secondary antibodies to human IgA, IgG, and IgM (Jackson
ImmunoResearch, West Grove, PA), followed by ortho-phenylenedi-
amine (Sigma, St. Louis,MO) in 0.1M sodium citrate buffer (pH 4.5) and
0.1% hydrogen peroxide for development. We read plates kinetically at
450 nm for 5 min and normalized the maximal rate of change in optical
density in milliabsorbance units per minute across plates by calculating
the ratio of the test sample to a standard of pooled convalescent-phase sera
from previously infected cholera patients included on each plate (15).We
considered individuals with a2-fold increase in anti-CtxB and LPS re-
sponses compared to their baseline to be responders.
DetectionofmemoryBcell (MBC) responsesby culture-based assay
usingELISPOT.WeassessedMBC responses toV. choleraeO1antigens as
previously described (13). In brief, we plated freshly harvested PBMCs in
24-well cell culture plates (BD Biosciences, San Jose, CA) at a concentra-
tion of 5  105 PBMC/well. To each well, we added culture medium
consisting of RPMI 1640 medium, 10% FBS, 200 U of penicillin/ml, 200
g of streptomycin/ml, 2 mM L-glutamine, and 50 M 2-mercaptoetha-
nol, with or without a stimulatory cocktail optimized to stimulate anti-
gen-independent proliferation and differentiation of memory B cells into
antibody-secreting cells (ASCs) (9). The mitogens used for stimulation
were 6 g of CpG oligonucleotide/ml (Operon, Huntsville, AL), a
1/100,000 dilution of crude pokeweed mitogen extract, and a 1/10,000
dilution of fixed Staphylococcus aureusCowan (Sigma, St. Louis,MO).We
incubated the plates at 37°C in a 5%CO2 incubator for 6 days, after which
the cells were harvested and washed. For the enzyme-linked immunosor-
bent spot (ELISPOT) assay, we coated nitrocellulose-bottom plates (Ma-
han-4550; Millipore, Bedford, MA) with GM1 ganglioside (3 nM) fol-
lowed by recombinant CtxB (2.5 g/ml) or with V. cholerae O1 Ogawa
LPS (25 g/ml). As a negative control, we coated plates with keyhole
limpet hemocyanin ([KLH] 2.5 g/ml; Pierce Biotechnology, Rockford,
IL). We also coated plates with affinity-purified goat anti-human immu-
noglobulin (5 g/ml; Jackson Immunology ResearchWest Grove, PA) to
detect total IgG and IgA MBC responses. After the plates were blocked
with RPMI 1640 medium containing 10% FBS, we used 20% of the cells
from each well to assess total IgG and IgA ASC and 80% to detect antigen-
specific IgG and IgA ASC. We detected IgG and IgA ASC using horserad-
ish peroxidase-conjugated mouse anti-human IgG and IgA (Hybridoma
Reagent Laboratory, Baltimore, MD), respectively, followed by 3-amino-
9-ethyl carbazole (AEC) for developing the plates. We quantified the
number of ASC per well by using a stereomicroscope. Data were collected
independently by two individuals and then averaged. For inclusion in
analyses, we required sufficient stimulation of total antibody isotype-spe-
cific memory B cells (defined as a3-fold increase comparing stimulated
to nonstimulated wells), fewer than four antigen-specific cells in the cor-
responding sample’s unstimulated wells, and fewer than four antigen-
FIG 1 Vaccination and blood draw time line. Ab, plasma for vibriocidal and
antigen-specific antibody assays; MBC, PBMC isolation for memory B cell
assay; D, day.
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specific cells in the corresponding sample’s KLH well, as previously de-
scribed (2, 22). Application of these criteria resulted in the inclusion of
approximately 90% of all data. We expressed ELISPOT counts as the
percentage of antigen-specific memory B cells out of the total IgG or IgA
memory B cell population.
Statistical analyses. We assessed normality of the data using a Sha-
piro-Wilk test. We compared baseline characteristics with a Fisher exact
test for categorical variables and a Mann-Whitney U test for continuous
variables. We assessed differences in the magnitude of immune responses
between two groups with a Mann-Whitney U test. All reported P values
are two-tailed, with a cutoff of a P value of0.05 considered a threshold
for statistical significance.We performed analyses using GraphPad Prism,
version 5.0 (GraphPad Software, Inc., La Jolla, CA) and SPSS, version 17.0
(SPSS Inc., Chicago, IL).
RESULTS
Study population. We enrolled 20 young children (aged 2 to 5
years; mean, 56months old; median, 60months old) and 20 older
children (aged 6 to 17 years;mean, 10.5 years old;median, 10 years
old) for administration of two doses of the WC-rBS oral cholera
vaccine 14 days apart. Ninety percent of the younger children and
100% of the older children completed 30 days of follow-up. We
compared the immune responses of these vaccinees to those of 38
patientsmatched for age group presenting with acute dehydrating
diarrhea and stool culture positive only forV. choleraeO1Ogawa.
All patients were treated per clinical protocol with intravenous
and oral fluid replacement therapy and azithromycin. Other than
age, there were no significant differences between older and
younger vaccinee age groups in gender or blood group, and there
were no differences between vaccinees and the age group-matched
patients by gender or blood group (Table 1). Infected children had
a mean weight-to-height Z score of1.4.
Vibriocidal response in plasma.Wemeasured vibriocidal re-
sponses to V. cholerae O1 Ogawa prior to and after vaccination.
The baseline geometric mean titer (GMT) in the younger and
older child vaccinee cohorts were 37 and 32, respectively. These
were not significantly different from baseline titers of age-
matched patients (15 and 34, respectively). Vibriocidal responses
were significantly higher by day 3 after the first dose of vaccine in
both younger (P  0.007) and older (P  0.008) children and
reached a peak at day 7 after the second dose (Fig. 2). Sixty-five
percent of the younger vaccinees and 90% of older pediatric vac-
cinees achieved a4-fold increase by day 7 after the second dose
of vaccine compared to baseline (P  0.13 for the comparison
between age groups). Vibriocidal titers were comparable between
vaccinee age groups at all days examined although a subanalysis
disclosed that vibriocidal responses in vaccinees of4 years of age
(n 5) were significantly lower on day 7 after the second dose of
vaccine than responses in older vaccinees (n 35, P 0.01). In
comparison, age-matched patients had significantly higher
vibriocidal titers at both day 7 and day 30 after infection than
vaccinees (P  0.001 for both age groups). A subanalysis
showed that in both vaccinees and patients, the baseline vibrio-
cidal titer negatively correlated with fold change in titer at day
7 (P  0.001).
V. cholerae-specific antibody responses in plasma. We as-
sessed antibody responses to the V. cholerae antigens LPS and
CtxB in plasma. Both vaccinee age groups had IgA and IgG plasma
responses to CtxB and IgA, IgG, and IgM responses to LPS that
were significantly higher than baseline values at day 7 after the
second dose of vaccine (Fig. 3 and 4).No differences were detected
inmagnitude or responder frequency in a comparison of anti-LPS
responses in older and younger vaccine recipients, but older chil-
TABLE 1 Demographic and clinical characteristics of study subjects
Subject characteristic
Value for subjects 2 to 5 yr old Value for subjects 6 to 17 yr old
WC-rBS vaccineesa
(n 20)
Cholera patients
(n 20) P
WC-rBS vaccineesa
(n 20)
Cholera patients
(n 18) P
No. that completed 30-day follow-up 18 18 20 17
Mean age (yr [range]) 4.7 (3–5) 4.2 (2–5) NSb 10.5 (7–14) 9.9 (6–16) NS
Female (no. [%]) 9 (45) 10 (50) NS 10 (50) 7 (39) NS
ABO blood group (no. [%])
A 5 (25) 3 (15) NS 4 (20) 5 (28) NS
B 4 (20) 4 (20) NS 6 (30) 7 (39) NS
AB 2 (10) 1 (5) NS 3 (15) 1 (6) NS
O 9 (45) 12 (60) NS 7 (35) 5 (28) NS
a WC-rBS, whole-cell recombinant B subunit oral cholera vaccine (Dukoral, Crucell, Sweden); n, number of participants.
b NS, nonsignificant.
FIG2 Geometricmean reciprocal vibriocidal antibody titers by age group and
vaccination status, with error bars representing 95% confidence intervals. An
asterisk denotes a significant difference (P 0.05) from the baseline (day 0 or
day 2) titer.
Leung et al.
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dren had higher day 7 and day 30 IgG responses against CtxB than
younger children (magnitude of response, P  0.05 at day 7 and
P 0.003 at day 30; responder frequency at day 30, 90% of older
children and 61%younger children,P 0.06). In general, levels of
CtxB antibodies did not significantly differ between vaccinees and
matched patients, except in younger children, where patients had
higher day 30 CtxB-specific IgG and day 7 CtxB-specific IgA than
vaccinees (Fig. 3). Younger patients also had higher peak levels of
IgG and IgA against LPS than their age-matched vaccine cohort on
day 7, and older patients had higher IgG, IgA, and IgM responses
against LPS than their age-matched vaccine cohort on day 30 (Fig.
4). There was no significant difference in the magnitude of anti-
LPS responses between younger and older children recovering
from wild-type disease at any time point.
Antigen-specificmemoryB cell responses.Weassessedmem-
ory B cell (MBC) responses to LPS and CtxB on day 0 (prevacci-
nation) and day 30 after the second dose of vaccine compared to
day 2 (acute phase) and day 30 (convalescence), respectively, fol-
lowing wild-type disease. On each day examined, younger and
older child vaccinees had comparable levels of detectable memory
B cells, and when results were analyzed by age cohort, no signifi-
cant MBC responses to CtxB or LPS were detected following vac-
cination with OCV (Fig. 5). When the data were analyzed com-
bining all pediatric vaccinees into one cohort, we were able to
detect a small but significant increase in CtxB-specific IgG mem-
ory B cell responses in vaccinees on day 30 following the second
immunization (P 0.03) (Fig. 6C), with a trend toward an LPS-
specific IgGmemory B cell response (P 0.08) (Fig. 6A). In com-
parison, we were able to detect significant increases in CtxB-spe-
cific IgG memory B cell responses 30 days following infection in
cholera patients when we analyzed data both in aggregate (P 
0.003) (Fig. 6C) and by age cohort (young children day 30 CtxB-
specific IgGMBC, P 0.02 compared to day 2) (data not shown).
Similarly, we detected significant LPS-specific memory B cell
responses in children recovering from cholera when we ana-
lyzed data both in aggregate (LPS-specific day 30 IgGMBC, P
0.015; LPS-specific day 30 IgAMBC, P 0.003) (Fig. 6A and B)
and by age cohort (LPS-specific day 30 IgA MBC compared to
day 2, P  0.03 for young children and P  0.06 for older
children) (data not shown) but not in vaccinees, irrespective of
the analysis approach.
DISCUSSION
Cholera affects all age groups. In zones of endemicity, young chil-
dren are vulnerable (10), andby adolescencemost have serological
evidence of previous exposure toV. choleraeO1 (25). During out-
breaks of cholera in zones where cholera is not endemic, children
and adults are equally affected by cholera (21, 24). As such, chil-
dren bear a very large burden of cholera globally (10). Despite this,
current oral cholera vaccines are associated with lower protective
efficacy and a shorter duration of protection in younger children
than observed following vaccination of adults (7, 38, 40). In addi-
tion, vaccination against cholera is also associated with lower lev-
els of protection and a shorter duration of protection than wild-
type infection with V. cholerae O1 provides (19, 36), despite the
fact that protection by wild-type infection against subsequent
cholera appears to be similar in younger children and older per-
sons (4). The immunologic correlates of these differences are
poorly understood, especially in children. Here, we show that
immune responses to an oral killed cholera vaccine (WC-rBS) are
generally comparable in younger and older children in an area
where cholera is endemic; however, these responses are much
lower than those detected following wild-type cholera infection,
most notably in anti-LPS responses in plasma, the vibriocidal re-
sponse, and memory B cell responses to LPS.
The vibriocidal antibody is the most-studied immunologic
marker of cholera infection and is an indirect/surrogatemarker of
protection. While vibriocidal titers correlate with protection
against cholera, there is no threshold at which protection is com-
plete (34). The vibriocidal response can be largely removed by
adsorption of plasma to LPS, strongly suggesting that antibodies
reacting with LPS are a critical component of the vibriocidal re-
sponse (26). Few direct comparisons have been made of the dif-
ferences in vibriocidal responses to OCV between younger and
FIG 3 Mean plasma antibody IgG (A) and IgA (B) responses to CtxB by age group as measured by ELISA, with error bars representing standard errors of the
means. An asterisk denotes a significant difference (P 0.05) from the baseline (day 2).
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older children. In immunogenicity studies ofWC-rBS in Peruvian
children, younger and older children had comparable seroconver-
sion rates 14 days after the second dose of vaccine (39). In our
study, we similarly found no differences in vibriocidal responses
between younger and older vaccinated children although a suba-
nalysis disclosed that the youngest children (defined as4 years of
age) were less able to mount a vibriocidal response than older
children. However, we did find that age-matched patients with V.
cholerae O1 Ogawa infection had significantly higher responses
(both inmagnitude and responder frequency) than vaccinees at all
days evaluated.
We have previously shown that LPS and CtxB plasma IgA an-
tibody responses correlate with protection against cholera in
household contacts of cholera patients (14). In our current study,
we now show that two doses ofWC-rBS vaccination induce prom-
inent IgA and IgG anti-CtxB responses in younger and older pe-
diatric vaccine recipients and that these responses are generally
comparable to those induced in children with wild-type cholera
infection, differing only in day 30 IgG and day 7 IgA responses in
the younger children. These similarities may in part reflect that
each dose of WC-rBS is supplemented with 1 mg of recombinant
CtxB. It should be noted that an alternative OCV, bivWC (Shan-
chol), does not contain supplemental CtxB, and the anti-CtxB
responses induced by WC-rBS (Dukoral) and bivWC (Shanchol)
may well be different. Despite our ability to detect prominent
anti-CtxB responses following vaccination of children with
WC-rBS and after wild-type disease, we found a marked differ-
ence between anti-LPS plasma responses in vaccinees versus chil-
dren recovering from wild-type cholera disease in both age
groups. Specifically, although vaccination induced low-level
plasma IgG, IgA, and IgM responses against LPS that were similar
in younger and older children, these responses were much lower
than those observed following wild-type disease in age-matched
controls.
FIG 4 Mean plasma antibody IgG (A), IgA (B), and IgM (C) responses to LPS by age group as measured by ELISA, with error bars representing standard errors
of the means. An asterisk denotes a significant difference (P 0.05) from the baseline (day 2).
Leung et al.
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Immunity against cholera following wild-type disease is be-
lieved to last at least 3 to 10 years (4, 19, 23). Since acute-phase
immune responses including vibriocidal and plasma antibody
responses fall to baseline within 6 to 12 months of infection
(13), longer-term protection against cholera is probably af-
forded by the ability to mount anamnestic responses facilitated
by long-term memory responses (17). We have previously
found that anti-LPS and anti-CtxBmemory B cell responses are
induced following wild-type cholera infection and that these
responses persist even after the vibriocidal and plasma anti-
body responses have returned to baseline (13). In adults, we
have also demonstrated that oral cholera vaccination withWC-
rBS induces anti-CtxB memory B cell responses but not anti-
LPS memory responses (2).
In our current analyses, we have now extended this work.
When results were analyzed by age cohort, we were unable to
detect anti-LPS or anti-CtxB memory B cell responses in both
younger and older vaccine recipients although when we analyzed
in aggregate, we did detect IgG memory B cell responses against
CtxB in children receiving WC-rBS. In comparison, we were able
to detect significant MBC responses against CtxB and LPS in chil-
dren recovering from cholera when responses were analyzed both
by age cohort and in aggregate. The ability of both naturally in-
fected and vaccinated children to generate anti-CtxB memory re-
sponses may in part reflect that the cholera vaccine used in this
study contains 1 mg of recombinant CtxB per dose, as well as the
potential boosting of preexisting immune responses to the im-
munologically cross-reactive heat labile toxin (LT) of entero-
toxigenic E. coli (ETEC) (11), an infection that is endemic in
resource-limited areas of the world including Bangladesh (30).
However, the significance of these CtxB responses in protecting
against cholera is uncertain since there is no heterologous pro-
tection against cholera between V. cholerae O1 and O139, de-
spite the fact that that these serogroups express identical en-
terotoxins (29), and since protective efficacy of oral cholera
vaccines containing and not containing supplemental CtxB are
comparable (7).
No difference has been noted in the degree of protection
against subsequent disease afforded by previous cholera infection
in younger and older children in areas of endemicity (4); however,
following vaccination, young children have a significantly shorter
duration and lower level of protection than older persons (7, 38,
40). In our current study, we found that the plasma antibody
against LPS, the memory B cell response against LPS, and vibrio-
cidal responses (largely targeting LPS) are significantly lower in
child vaccinees than in children recovering fromwild-type cholera
infection. This is particularly significant when we consider that
responses against LPS may be a prime mediator of protection
against cholera (11, 14, 29).
LPS is a T cell-independent antigen (16), and young children
are less able to mount T cell-independent responses than older
children and adults (18). Our inability to detect differences in
acute and MBC responses against LPS in comparing cohorts of
younger and older children following vaccination in this analysis
FIG 5 Mean antigen-specific IgG (A and C) and IgA (B and D) memory B cell responses, as percentages of total memory B cells, with error bars representing
standard errors of the means, by vaccinee age group.
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may in part reflect the relatively small size of our vaccine cohorts
and the fact that themean age of our cohort of5 years of age was
4.7 years. As such, many of these young children in this area of
high endemicity for cholera may already have been exposed to V.
cholerae (33), mitigating our ability to detect differences in
younger versus older vaccine recipients. This possibility is further
supported by the fact that we were able to detect a significant
increase in both plasma IgG and IgA to both CtxB and LPS within
3 days of administration of oral cholera vaccine even in the cohort
of children 5 years old in this study, suggesting prior exposure
and a primed response. Similarly, the observation in our suba-
nalysis that the youngest vaccinees in this study were less able to
mount a vibriocidal response than older vaccinees supports this
hypothesis. Whether we would have found similar results if we
had conducted the study in an area where cholera is not endemic
or if we had focused our enrollment and analysis on children less
than 3 years of age is uncertain. We also cannot exclude the pos-
sibility that vaccination induces low-level memory responses
against LPS in children but that these responses are below the level
of detection of our assay. Finally, our inability to specifically detect
differences in anti-LPS memory B cell responses between older
and younger vaccine recipientsmay also be due to the fact that oral
cholera vaccines are particularly poor inducers of LPS-specific
memory B cell responses, even in immunologically primed adults
(2), and this reality complicates our ability to detect differences
between younger and older children for this immunologic
marker.
A potential shortcoming of our study is that our group and
others have demonstrated the effect of zinc supplementation (1, 3,
28), small bowel bacterial overgrowth (20), and antiparasitic drug
treatment (8) on immune responses to OCV in young children.
We did not assess differences between age groups of such modifi-
ers of immune responses in this study, and these factors deserve
further investigation. Furthermore, difficulties in recruiting child
participants, especially those less than 4 years of age, limited our
sample size.
In conclusion, in this study we demonstrate that both younger
and older children vaccinated with a WC-rBS oral killed cholera
vaccine formulationmount comparable immune responses in this
area of high endemicity for cholera where prior exposure may
have occurred but that these responses, especially vibriocidal and
LPS responses, including memory B cell responses, are signifi-
cantly lower than the responses detected in age-matched children
recovering from natural cholera infection requiring hospitaliza-
tion. These observations are significant and may in part explain
differences in protective efficacy and duration of protection ob-
FIG 6 Mean antigen-specific IgG (A and C) and IgA (B and D) memory B cell responses, as percentages of total memory B cells, with error bars representing
standard errors of the means. Data represent combined age group analysis.
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served betweenwild-type infection and vaccinationwith currently
available oral cholera vaccines.
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